Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein–Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol

References

• Lim MS, Leval Ld, Quintanilla-Martinez L. Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms. J Hematopathol. 2009;2(2):65–73.
   PubMedGoogle Scholar
• Julie V, James A, Dennis W. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Li YX, Liu QF, Fang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 2009;15(8):2905–2912.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24(4):612–618.
   PubMed Web of Science ®Google Scholar
• Ko YH, Ree HJ, Kim WS, et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer. 2000;89(10):2106–2116.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Anderson BO, Advani R, et al. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10(11):1093.
   PubMed Web of Science ®Google Scholar
• Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19(12):2186–2194.
   PubMed Web of Science ®Google Scholar
• Ishida F, Kwong YL. Diagnosis and management of natural killer-cell malignancies. Expert Rev Hematol. 2010;3(5):593–602.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121(25):4997–5005.
   PubMed Web of Science ®Google Scholar
• Kieff E, Rickinson, AB. (2007) Epstein-Barr virus and its replication. Fields Virology, 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 2603–2654.
   Google Scholar
• Williams H, Crawford DH. Epstein–Barr virus: the impact of scientific advances on clinical practice. Blood. 2006;107(3):862.
   PubMed Web of Science ®Google Scholar
• Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350(24):2461.
   PubMed Web of Science ®Google Scholar
• Lo YM, Chan LY, Chan AT, et al. Quantitative and temporal correlation between circulating cell-free Epstein–Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999;59(21):5452.
   PubMed Web of Science ®Google Scholar
• Chan KA. Plasma Epstein–Barr virus DNA as a biomarker for nasopharyngeal carcinoma. Chin J Cancer. 2014;33(12):598–603.
   PubMedGoogle Scholar
• Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004;104(1):243–249.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Yamaguchi M, Izutsu K, et al. Prospective measurement of Epstein–Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118(23):6018.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Liu QF, Wang H, et al. Clinical implications of plasma Epstein–Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012;120(10):2003.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang H, Wang J, et al. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015;6(30):30317.
   PubMed Web of Science ®Google Scholar
• Wang B, Li XQ, Ma X, et al. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 2008;83(10):795–799.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410–4416.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973–2980.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Gachard N, Marin B, et al. Efficacy of l-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834.
   PubMed Web of Science ®Google Scholar
• Gao Y, Huang HQ, QiChun C, et al., Efficacy and safety of pegaspargase with gemcitabine and oxaliplatin in patients with treatment-naive, refractory extranodal natural killer/T-cell lymphoma: a single-center experience. Blood. 2013;122(21):Abstract, 642.
   Google Scholar
• Jaffe ES, Swerdlow SH, Campo E, et al. WHO classification of tumours of the haematopoietic and lymphoid tissues; Lyon: IARC Press, 2008. p. 285–288.c 2008.
   Google Scholar
• Fryer JF, Heath AB, Wilkinson DE, et al. A collaborative study to establish the 1st WHO International Standard for Epstein–Barr virus for nucleic acid amplification techniques. Biologicals. 2016;44(5):423–433.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.
   PubMed Web of Science ®Google Scholar
• Kim Y. Quantification of circulating Epstein–Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia. 2014;28(4):865–870.
   PubMed Web of Science ®Google Scholar
• Lei KI, Chan LY, Chan WY, et al. Diagnostic and prognostic implications of circulating cell-free Epstein–Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res. 2002;8(1):29–34.
   PubMed Web of Science ®Google Scholar
• Ishii H, Ogino T, Berger C, et al. Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for nasal NK/T-cell lymphoma. J Med Virol. 2007;79(5):562.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim KH, Kim KH, et al. Whole blood Epstein–Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2009;50(5):757.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kimura H, Maeda Y, et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type. Clin Cancer Res. 2012;18(15):4183–4190.
   PubMed Web of Science ®Google Scholar